130 results
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
18 Jun 24
Other Events
7:37am
adequate reimbursement from third-party payors; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indications
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
or other challenges in commercializing CAPLYTA; whether CAPLYTA receives adequate reimbursement from third-party payors; the degree to which CAPLYTA
424B5
ITCI
Intra-Cellular Therapies Inc
18 Apr 24
Prospectus supplement for primary offering
5:23pm
payers or if patients are unable to obtain adequate levels of reimbursement.
Public health threats could have a material impact on our business … candidates;
the election by any collaborator to pursue research, development and commercialization activities;
our ability to obtain future reimbursement
424B5
wm1jn7nl kpj
16 Apr 24
Prospectus supplement for primary offering
4:37pm
S-3ASR
EX-4.11
uvv al607p30jlk
16 Apr 24
Automatic shelf registration
4:01pm
S-3ASR
oshk dz8mgwxiu
16 Apr 24
Automatic shelf registration
4:01pm
S-3ASR
EX-4.10
qm9diqu
16 Apr 24
Automatic shelf registration
4:01pm
8-K
j4t5c8xlg7t6lna
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-99.1
q823mdh2c66v
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
8-K
EX-99.1
15nq2mi
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
EX-99.1
tqnum0rqz5s2r
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
EX-99.1
p8i8uypxujrkc
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am
8-K
EX-99.1
nophi5x5vg 3o3bhyxe
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am